Eli Lilly and Company

Pharmaceuticals

LLY

$ 765 (0.9)%

Share price

$ 727 bn

Market Cap

$ 712 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.03x the weighted average for S&P 500

FY2020

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Eli Lilly and Company reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 710 Kt (-78 /-9.9% y-o-y). Also positively, carbon intensity plunged to 29 t (-6.4 /-18.1% y-o-y).

Eli Lilly and Company's Scope 3 emissions plummeted to 176 Kt (-59 /-25.1% y-o-y). The decline accelerated compared to the CAGR of -12.5% since 4Q'18.

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Date	Total CO2e emissions (location-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2020Q4	710	159	551	176	24,540	29
2019Q4	788	192	671	235	22,320	35
2018Q4	855	201	983	263	21,493	40
2017Q4	864	228	985	232	22,871	38
2016Q4	876	216	1,009	248	21,222	41
2015Q4	927	214	713	237	19,959	46
2014Q4	1,580	460	1,120	289
2012Q4	965	220	745	266

Eli Lilly and Company

Carbon footprint

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

GHG emissions and Carbon intensity

Eli Lilly and Company's carbon footprint

Company environmental metrics